ArticleAdvances in urology2026
The Impact of Intraoperative Dexamethasone and Mannitol on Postoperative Inflammatory Response in Totally Tubeless Percutaneous Nephrolithotomy: A Prospective, Double-Blind, Controlled Clinical Trial.
Article in Advances in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Dexamethasone, a corticosteroid, reduces inflammation, while mannitol, a diuretic, improves renal blood flow and stone clearance. This study examines the impact of dexamethasone and mannitol during surgery on infection rates, pain control, and analgesic needs in totally tubeless PCNL (TTPCNL) patients. Methods: This double-blind, controlled clinical trial at a single center involved 121 patients undergoing TTPCNL. Participants were randomly divided into four groups: control, dexamethasone, mannitol, and dexamethasone-mannitol (DM). Postoperative outcomes included pain intensity measured using the visual analog scale (VAS) at 6 and 24 hours after tubleless PCNL. Patients with moderate-to-severe pain received rescue analgesia (paracetamol and ketorolac). Additional outcomes included length of hospital stay (LOS), serum interleukin-6 (IL-6) levels, gross hematuria, stone-free rate (SFR), Clavien-Dindo grade (CDG), and postoperative complications, including sepsis, systemic inflammatory response syndrome (SIRS), hemoglobin decline, the need for angiography, hospital readmission, and acute kidney injury (AKI). Results: This study included 81 male participants (66.9%), with a mean age of 50.9 ± 12.2 years. Patients treated with dexamethasone, either alone or with mannitol, showed significant reductions in postoperative SIRS ( Conclusions: The intraoperative use of dexamethasone and mannitol during TTPCNL effectively mitigated postoperative inflammatory responses. This was achieved by reducing levels of IL-6 and decreasing the occurrence of SIRS. Additionally, patients experienced a shorter postoperative hospital stay, lower VAS pain score, lower CDG, and lower analgesic consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.